You just read:

Regeneron and Sanofi Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis

News provided by

Regeneron Pharmaceuticals, Inc.

17 Nov, 2016, 02:00 ET